CTOR Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of 10.24%. Citius Oncology, Inc.'s return on equity of -64.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 424.02%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that Citius Oncology, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Citius Oncology, Inc. is more attractive than Amicus Therapeutics, Inc..

Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Citius Oncology, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Citius Oncology, Inc.'s net income of -$5M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GT Biopharma, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of --. Citius Oncology, Inc.'s return on equity of -64.23% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 424.02%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe GT Biopharma, Inc. is more attractive than Citius Oncology, Inc..

Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Citius Oncology, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Soligenix, Inc. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of -1636.63%. Citius Oncology, Inc.'s return on equity of -64.23% beat Soligenix, Inc.'s return on equity of -248.07%.

Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 424.02%. On the other hand Soligenix, Inc. has an analysts' consensus of $17.50 which suggests that it could grow by 1115.28%. Given that Soligenix, Inc. has higher upside potential than Citius Oncology, Inc., analysts believe Soligenix, Inc. is more attractive than Citius Oncology, Inc..

Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soligenix, Inc. has a beta of 1.834, suggesting its more volatile than the S&P 500 by 83.414%.

Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soligenix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Soligenix, Inc. pays out -- of its earnings as a dividend.

Citius Oncology, Inc. quarterly revenues are --, which are smaller than Soligenix, Inc. quarterly revenues of --. Citius Oncology, Inc.'s net income of -$5M is lower than Soligenix, Inc.'s net income of -$2.5M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Soligenix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus -- for Soligenix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding Corp. has a net margin of -- compared to Citius Oncology, Inc.'s net margin of -972.95%. Citius Oncology, Inc.'s return on equity of -64.23% beat Tonix Pharmaceuticals Holding Corp.'s return on equity of -62.54%.

Citius Oncology, Inc. has a consensus price target of $6.00, signalling upside risk potential of 424.02%. On the other hand Tonix Pharmaceuticals Holding Corp. has an analysts' consensus of $66.33 which suggests that it could grow by 295.19%. Given that Citius Oncology, Inc. has higher upside potential than Tonix Pharmaceuticals Holding Corp., analysts believe Citius Oncology, Inc. is more attractive than Tonix Pharmaceuticals Holding Corp..

Citius Oncology, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding Corp. has a beta of 1.817, suggesting its more volatile than the S&P 500 by 81.674%.

Citius Oncology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology, Inc. pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding Corp. pays out -- of its earnings as a dividend.

Citius Oncology, Inc. quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding Corp. quarterly revenues of $3.3M. Citius Oncology, Inc.'s net income of -$5M is higher than Tonix Pharmaceuticals Holding Corp.'s net income of -$32M. Notably, Citius Oncology, Inc.'s price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology, Inc. is -- versus 9.05x for Tonix Pharmaceuticals Holding Corp.. Usually stocks with elevated PS ratios are considered overvalued.